Growth Hormone Therapy in Short Stature Children
Journal of the Korean Medical Association
; : 849-855, 2008.
Artigo
em Coreano
| WPRIM (Pacífico Ocidental)
| ID: wpr-90572
Biblioteca responsável:
WPRO
ABSTRACT
Since 1985 recombinant DNA-derived human growth hormone (hGH) became available for treatment of various growth disorders in children. GH stimulates linear growth in children with growth hormone deficiency (GHD) and also demonstrates efficacy in the treatment of Turner syndrome, chronic renal failure, Prader-Willi syndrome, and growth failure secondary to small for gestational age (SGA). Although recently FDA approved GH therapy for idiopathic short stature, the effect of GH treatment remains unclear. GH therapy is generally safe but GH has potential side effects. The decision of GH therapy in idiopathic short stature should be made individualized under consideration of the efficacy, cost-effectiveness, and psychosocial aspects, and GH therapy must be carried out by pediatric endocrinologists or experienced physicians.
Texto completo:
Disponível
Base de dados:
WPRIM (Pacífico Ocidental)
Assunto principal:
Síndrome de Prader-Willi
/
Síndrome de Turner
/
Hormônio do Crescimento
/
Idade Gestacional
/
Hormônio do Crescimento Humano
/
Transtornos do Crescimento
/
Falência Renal Crônica
Limite:
Criança
/
Humanos
Idioma:
Coreano
Revista:
Journal of the Korean Medical Association
Ano de publicação:
2008
Tipo de documento:
Artigo